DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
A multicenter, randomized, double-blind, phase 3 study of ramucirumab (IMC-1121B) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib (REACH).
Available at:
http://clinicaltrials.gov/ct2/show/NCT01140347 . Accessed January 11, 2012
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.